PHOENIX, Ariz., and DANVILLE, Pa. Feb. 3, 2010 The Translational Genomics Research Institute (TGen) and Geisinger Health System today announced the signing of a strategic research agreement that provides for a focused look at the gaps in clinical medicine where biomedical research can make a difference.
One of the first projects will focus on the causes of obesity, diabetes and other metabolic conditions. Researchers plan to look at the possible genetic reasons why so many Americans are overweight, and why diet, exercise and, specifically, bariatric surgery may fail to significantly reduce excess weight in some patients.
TGen, a non-profit biomedical research institute based in Phoenix, will pair its genomic and proteomic research expertise with the clinical excellence and research expertise of Geisinger, a non-profit medical and insurance provider based in Danville, Pa.
Geisinger's strength is its integrated healthcare delivery model, nontransitory population and advanced electronic health record (EHR) with nearly two decades of data. In addition to providing the clinical underpinnings for the study of obesity, the data within the EHR will provide researchers the evidence they need to make discoveries in future projects centered on cancer and other serious diseases.
"Merging Geisinger's wealth of clinical information with our genomic and proteomic expertise should provide researchers a richer framework for exploring the genetic origins of disease, and hopefully lead to improved treatments and outcomes," said Dr. Jeffrey Trent, Ph.D., TGen's President and Research Director.
TGen emphasizes a translational research process intended to quickly turn laboratory discoveries into new drugs and other treatments that can benefit patients, a goal shared by Geisinger.
"Given our unique research structure and a patient population that overwhelmingly supports cutting-edge research, I am confident that this partnership
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute